A Cochrane review of the off-label use of FVIIa reported that FVIIa did not have a significant mortality benefit over placebo but showed a trend toward control of bleeding, a lower number of transfusions, and arterial thromboembolic events [ 93 ].
← all excerpts
Treatment of Diffuse Alveolar Hemorrhage: Controlling Inflammation and Obtaining Rapid and Effective Hemostasis.
1
—
—